Yury Kukushkin
Director/Board Member at Veralox Therapeutics, Inc.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Brian McVeigh | M | 51 |
Code Biotherapeutics, Inc.
Code Biotherapeutics, Inc. BiotechnologyHealth Technology Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation. | - |
Matthew B. Boxer | M | - |
Veralox Therapeutics, Inc.
Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Veralox Therapeutics, Inc. develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. The company was founded by Jeffrey W. Strovel, David J. Maloney and Matthew B. Boxer and is headquartered in Frederick, MD. | 7 years |
David J. Maloney | M | - |
Veralox Therapeutics, Inc.
Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Veralox Therapeutics, Inc. develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. The company was founded by Jeffrey W. Strovel, David J. Maloney and Matthew B. Boxer and is headquartered in Frederick, MD. | 7 years |
Ron Burkle | M | 70 |
Hevolution Foundation
| - |
Benjamin Scruggs | M | - |
Veralox Therapeutics, Inc.
Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Veralox Therapeutics, Inc. develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. The company was founded by Jeffrey W. Strovel, David J. Maloney and Matthew B. Boxer and is headquartered in Frederick, MD. | 3 years |
Jim Trenkle | M | - |
Veralox Therapeutics, Inc.
Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Veralox Therapeutics, Inc. develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. The company was founded by Jeffrey W. Strovel, David J. Maloney and Matthew B. Boxer and is headquartered in Frederick, MD. | - |
Victor Stone | M | - |
Code Biotherapeutics, Inc.
Code Biotherapeutics, Inc. BiotechnologyHealth Technology Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation. | 3 years |
Robert Lin | M | - |
Code Biotherapeutics, Inc.
Code Biotherapeutics, Inc. BiotechnologyHealth Technology Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation. | - |
Ibrahim AlSuwaiyel | M | - |
Hevolution Foundation
| - |
Erin Brubaker | F | - |
Code Biotherapeutics, Inc.
Code Biotherapeutics, Inc. BiotechnologyHealth Technology Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation. | 3 years |
Mohammed Al-Saud | M | - |
Hevolution Foundation
| - |
Yasir Al-Rumayyan | M | - |
Hevolution Foundation
| - |
Fahad Toonsi | M | - |
Hevolution Foundation
| - |
Fahd Al-Rasheed | M | - |
Hevolution Foundation
| - |
Munir Eldesouki | M | - |
Hevolution Foundation
| - |
Saleh Al-Qahtani | M | - |
Hevolution Foundation
| - |
S. Rouan | M | 61 |
Code Biotherapeutics, Inc.
Code Biotherapeutics, Inc. BiotechnologyHealth Technology Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation. | - |
Dmitry Kuzmin | M | - |
Code Biotherapeutics, Inc.
Code Biotherapeutics, Inc. BiotechnologyHealth Technology Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation. | - |
Jamie Stiff | M | - |
Veralox Therapeutics, Inc.
Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Veralox Therapeutics, Inc. develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. The company was founded by Jeffrey W. Strovel, David J. Maloney and Matthew B. Boxer and is headquartered in Frederick, MD. | - |
Peter Young | M | 74 |
Veralox Therapeutics, Inc.
Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Veralox Therapeutics, Inc. develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. The company was founded by Jeffrey W. Strovel, David J. Maloney and Matthew B. Boxer and is headquartered in Frederick, MD. | 1 years |
Andrew Liveris | M | 69 |
Hevolution Foundation
| - |
Jonathan Mow | M | 59 |
Veralox Therapeutics, Inc.
Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Veralox Therapeutics, Inc. develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. The company was founded by Jeffrey W. Strovel, David J. Maloney and Matthew B. Boxer and is headquartered in Frederick, MD. | 1 years |
Alex Martin Martin | M | 55 |
Veralox Therapeutics, Inc.
Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Veralox Therapeutics, Inc. develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. The company was founded by Jeffrey W. Strovel, David J. Maloney and Matthew B. Boxer and is headquartered in Frederick, MD. | 4 years |
Ed Mathers Mathers | M | 64 |
Code Biotherapeutics, Inc.
Code Biotherapeutics, Inc. BiotechnologyHealth Technology Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation. | - |
Steven St. Peter | M | 57 |
JDRF T1D Fund
JDRF T1D Fund Investment ManagersFinance JDRF T1D Fund (JDRF T1D Fund) is a venture capital subsidiary of JDRF International founded in 2011 by Sean Doherty. The firm is headquartered in Boston, Massachusetts. | 5 years |
Andreas Georgi | M | 67 |
Ludwig-Maximilians-Universität München
| 16 years |
Joseph Truitt | M | 59 |
Code Biotherapeutics, Inc.
Code Biotherapeutics, Inc. BiotechnologyHealth Technology Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation. | - |
Saud Al-Bawardi | M | 48 |
Hevolution Foundation
| - |
Alexander Dmitrievich Nekipelov | M | 72 |
Moscow State University Lomonosov
| 23 years |
Mehmood Khan | M | 66 |
Hevolution Foundation
| 4 years |
Ellen Leake | F | - |
JDRF T1D Fund
JDRF T1D Fund Investment ManagersFinance JDRF T1D Fund (JDRF T1D Fund) is a venture capital subsidiary of JDRF International founded in 2011 by Sean Doherty. The firm is headquartered in Boston, Massachusetts. | 4 years |
Russ Fein | M | - |
Code Biotherapeutics, Inc.
Code Biotherapeutics, Inc. BiotechnologyHealth Technology Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation. | - |
Alexander Nazarchuk | M | 55 |
Moscow State University Lomonosov
| 22 years |
Irina Sergeevna Shytkina | M | 59 |
Moscow State University Lomonosov
| 19 years |
Evgeny Lebedev | M | - |
Hevolution Foundation
| - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Tilman Steinert | M | - |
Ludwig-Maximilians-Universität München
| 10 years |
Sebastian Hofbeck | M | - |
Ludwig-Maximilians-Universität München
| 8 years |
Denis Borisovich Solovyov | M | 46 |
Moscow State University Lomonosov
| 6 years |
Konstantin Viktorovich Garanin | M | 49 |
Moscow State University Lomonosov
| 6 years |
Artem I. Zassoursky | M | 45 |
Moscow State University Lomonosov
| 6 years |
George Ilyich Rizhinashvili | M | 43 |
Moscow State University Lomonosov
| 6 years |
Vladimir Yuryevich Mamakin | M | 50 |
Moscow State University Lomonosov
| 7 years |
Philipp Birnstingl | M | - |
Ludwig-Maximilians-Universität München
| 5 years |
Sascha Riedl | M | - |
Ludwig-Maximilians-Universität München
| 5 years |
Sergey Pikin | M | 45 |
Moscow State University Lomonosov
| 6 years |
Yuriy Maksimov | M | 46 |
Moscow State University Lomonosov
| 7 years |
Yevgeniya Aleksandrovna Kozlova | F | 43 |
Moscow State University Lomonosov
| 4 years |
Irina Aleksandrovna Marina | F | 41 |
Moscow State University Lomonosov
| 4 years |
Andrey Pavlovich Opekunov | M | - |
Moscow State University Lomonosov
| 4 years |
Denis Nayshul | M | - |
Moscow State University Lomonosov
| 5 years |
Kristina Galkina | F | 46 |
Moscow State University Lomonosov
| 4 years |
Alexey Serov | M | 45 |
Moscow State University Lomonosov
| 4 years |
Elena Vladimirovna Sapozhnikova | F | 46 |
Moscow State University Lomonosov
| 4 years |
Yekaterina Nikolayevna Klyuchnikova | F | - |
Moscow State University Lomonosov
| 4 years |
Dmitry Galperin | M | - |
Moscow State University Lomonosov
| 8 years |
Leonid Veniaminovich Zabezhinskiy | M | 64 |
Moscow State University Lomonosov
| 4 years |
Alexander Sannikov | M | - |
Moscow State University Lomonosov
| 5 years |
Ivan Fedyunin | M | 37 |
Moscow State University Lomonosov
| 4 years |
Mikhail Kalashnikov | M | - |
Moscow State University Lomonosov
| 5 years |
Elena Anatolyevna Gorskaya | F | - |
Moscow State University Lomonosov
| 4 years |
Dmitry Kibkalo | M | - |
Moscow State University Lomonosov
| 5 years |
Egor Mikhailovich Sheibak | M | 38 |
Moscow State University Lomonosov
| 4 years |
Koreneva Oxana | M | - |
Moscow State University Lomonosov
| 2 years |
Mike Ionov | M | - |
Moscow State University Lomonosov
| 6 years |
Alexey Nikolaevich Simonov | M | 52 |
Moscow State University Lomonosov
| 5 years |
Kuat Irubayev | M | 45 |
Moscow State University Lomonosov
| 5 years |
Vadim Pushkarev | M | - |
Moscow State University Lomonosov
| 5 years |
Vasiliy Mikhaylovich Belov | M | 42 |
Moscow State University Lomonosov
| 4 years |
Elizaveta Rozhdestvenskaya | M | - |
Moscow State University Lomonosov
| 5 years |
Denis Anatolyevich Afanasov | M | 44 |
Moscow State University Lomonosov
| 3 years |
Anatoliy Gavrilenko | M | 51 |
Moscow State University Lomonosov
| 3 years |
Igor Konstantinovich Danilenko | M | 41 |
Moscow State University Lomonosov
| 4 years |
Nikolay Sobolev | M | 47 |
Moscow State University Lomonosov
| 3 years |
Anton Mironenkov | M | 48 |
Moscow State University Lomonosov
| 4 years |
Anton Uvarov | M | - |
Moscow State University Lomonosov
| 5 years |
Natalia Sergunina | F | 45 |
Moscow State University Lomonosov
| 3 years |
Anton I. Smetanin | M | 39 |
Moscow State University Lomonosov
| 3 years |
Sergey Andreevich Tribunsky | M | 37 |
Moscow State University Lomonosov
| 4 years |
Dmitri Vladimirovich Boulkhoukov | M | 44 |
Moscow State University Lomonosov
| 4 years |
Pavel Sukholinskiy | M | 46 |
Moscow State University Lomonosov
| 2 years |
Alexander Novak | M | 52 |
Moscow State University Lomonosov
| 4 years |
Aybar Koshkinbaevich Burkitbaev | M | 57 |
Moscow State University Lomonosov
| 2 years |
Ivan Vyacheslavovich Savelyev | M | 40 |
Moscow State University Lomonosov
| 4 years |
Valeriy Nikolayevich Khlebnov | M | 56 |
Moscow State University Lomonosov
| 3 years |
Victor Anatolievich Isakov | M | 55 |
Moscow State University Lomonosov
| 3 years |
Anna Ilnitskaya | F | - |
Moscow State University Lomonosov
| 4 years |
Boris Borisovich Kim | M | 59 |
Moscow State University Lomonosov
| 4 years |
Timur Abylgaziev | M | 40 |
Moscow State University Lomonosov
| 4 years |
Stanislav Viktorovich Bliznyuk | M | 44 |
Moscow State University Lomonosov
| 4 years |
Dmitry Aleksandrovich Kobzar | M | 44 |
Moscow State University Lomonosov
| 3 years |
Pavel Yunin | M | - |
Moscow State University Lomonosov
| 6 years |
Maxim Aleksandrovich Polovinkin | M | 49 |
Moscow State University Lomonosov
| 4 years |
Ilya Guschin | M | 48 |
Moscow State University Lomonosov
| 5 years |
Larisa Fedorovna Tikhomirova | F | 40 |
Moscow State University Lomonosov
| 4 years |
Maxim Lapin | M | 44 |
Moscow State University Lomonosov
| 4 years |
Dmitriy Valeryevich Kulakovskiy | M | 45 |
Moscow State University Lomonosov
| 4 years |
Nataliya Erpsher | F | 55 |
Moscow State University Lomonosov
| 4 years |
Leopold Freiherr von Schönau-Wehr | M | 38 |
Ludwig-Maximilians-Universität München
| 3 years |
Ivan Nikolaevich Zyuzin | M | 41 |
Moscow State University Lomonosov
| 4 years |
Rostislav Shorgin | M | - |
Moscow State University Lomonosov
| 5 years |
Statistics
Country | Connections | % of total |
---|---|---|
Russia | 63 | 63.00% |
United States | 19 | 19.00% |
Saudi Arabia | 12 | 12.00% |
Germany | 6 | 6.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Yury Kukushkin
- Personal Network